Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consolidated Alcon Eye Division Has Key Role In Maintaining Novartis’ Growth

Executive Summary

Like many other big pharma companies, Novartis AG faces an imminent patent cliff, with blood pressure blockbuster Diovan (valsartan), among other products, due to lose patent protection soon.

You may also be interested in...

NicOx Kicks Off Specialty Ophthalmics Transformation With Altacor Buy

France's NicOx, aiming to transform into a specialty ophthalmology company after several late-stage disappointments, announced plans to acquire VC-backed U.K startup Altacor.

Alcon Grabs Ex-U.S. Rights To ThromboGenics' Retina Adhesion Therapy Ocriplasmin In $500 Mil. Deal

Novartis' ophthalmic unit Alcon will collaborate with Belgium's ThromboGenics on the marketing and future development of the vitreomacular adhesion therapy, ocriplasmin.

Novartis Boosted By Alcon, Generic Sales And Gilenya Launch in Second Quarter

Novartis lifted by strong sales of recently launched products in the second quarter, and by strong growth in its Alcon, generics and consumer health divisions.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts